[go: up one dir, main page]

MX2010001572A - Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. - Google Patents

Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Info

Publication number
MX2010001572A
MX2010001572A MX2010001572A MX2010001572A MX2010001572A MX 2010001572 A MX2010001572 A MX 2010001572A MX 2010001572 A MX2010001572 A MX 2010001572A MX 2010001572 A MX2010001572 A MX 2010001572A MX 2010001572 A MX2010001572 A MX 2010001572A
Authority
MX
Mexico
Prior art keywords
treamtent
egfr inhibitor
predictive marker
predictive
marker
Prior art date
Application number
MX2010001572A
Other languages
English (en)
Inventor
Verena Lutz
Paul Delmar
Barbara Klughammer
Patricia Mcloughlin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010001572A publication Critical patent/MX2010001572A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un biomarcador que es predictivo para el beneficio clínico al tratamiento con el inhibidor de EGFR en pacientes con cáncer.
MX2010001572A 2007-08-14 2008-08-07 Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. MX2010001572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114305 2007-08-14
PCT/EP2008/006518 WO2009021679A1 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treamtent

Publications (1)

Publication Number Publication Date
MX2010001572A true MX2010001572A (es) 2010-03-15

Family

ID=39789783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001572A MX2010001572A (es) 2007-08-14 2008-08-07 Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Country Status (9)

Country Link
EP (1) EP2176429A1 (es)
JP (1) JP2010535520A (es)
KR (1) KR20100037633A (es)
CN (1) CN101802221A (es)
AU (1) AU2008286412A1 (es)
BR (1) BRPI0815372A2 (es)
CA (1) CA2695318A1 (es)
MX (1) MX2010001572A (es)
WO (1) WO2009021679A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646249A (en) * 1994-02-28 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Isolation and characterization of a novel chaperone protein
EP1636380A2 (en) * 2003-05-30 2006-03-22 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
KR101126560B1 (ko) * 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법

Also Published As

Publication number Publication date
BRPI0815372A2 (pt) 2019-09-24
AU2008286412A1 (en) 2009-02-19
WO2009021679A1 (en) 2009-02-19
EP2176429A1 (en) 2010-04-21
KR20100037633A (ko) 2010-04-09
CA2695318A1 (en) 2009-02-19
CN101802221A (zh) 2010-08-11
JP2010535520A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
WO2010017515A3 (en) Breast cancer specific markers and methods of use
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EA201171367A1 (ru) Винилиндазолильные соединения
IN2012DN03012A (es)
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
CR9301S (es) Cuerpo de grifo
MX2013003880A (es) Metodo para diagnostico, pronostico y tratamiento de la metastasis de carcer de mama.
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
FR2912304B1 (fr) Instrument de reduction de fracture de corps osseux.
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2010001571A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
WO2010015538A3 (en) Predictive marker for egfr inhibitor treatment
WO2008054598A8 (en) Panel of biomarkers for prediction of fti efficacy
MX2010001573A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001577A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001583A (es) Maracdor predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
BR112013009143A2 (pt) método in vitro, uso e invenção
MX2010001570A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001578A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001572A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001579A (es) Maracador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001582A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
TN2009000448A1 (en) Use of hdac inhibitors for the treatment of bone destruction

Legal Events

Date Code Title Description
FA Abandonment or withdrawal